Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
EMD Serono's Biologic Bavencio (Avelumab) Receives Approval in the U.S.
Patients with mismatch repair–deficient and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (CRC) experienced a progression-free survival (PFS) benefit with longer disease control following treatment with avelumab (Bavencio) compared with standard second-line chemotherapy, according to findings from the phase 2 SAMCO-PRODIGE 54 trial (NCT03186326) published in JAMA Oncology.
The addition of first-line maintenance avelumab (Bavencio) to best supportive care (BSC) has sustained tolerability in patients with advanced urothelial carcinoma, according to long-term post hoc safety findings from the phase 3 JAVELIN Bladder 100 trial (NCT02603432) that were presented at the 2023 ASCO Annual Meeting.
SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- Genome & Company (CEOs: Pae, Jisoo, Park, Hansoo), a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim analysis.
Merck KGaA reported Monday that it had regained full rights to its PD-L1 antibody Bavencio after a nearly 10-year alliance with Pfizer was terminated.
Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)
New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma
NEW YORK, Dec. 8, 2022 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today presented Phase 2a clinical safety and efficacy data on lead therapeutic candidate PT-112 in combination with PD-L1 inhibition, in patients with advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2022.